News

Alcon Sees Surge in Shares Following Positive Results for Dry-Eye Treatment

1 Mins read

Swiss pharmaceutical company Alcon experienced a notable rise in shares on Wednesday after announcing positive results for its dry-eye disease treatment in two trials.

At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46, reaching a high of CHF70.20.

Alcon confirmed on Tuesday that its candidate drug, AR-15512, successfully achieved its primary goals with statistical significance in treating dry-eye disease. The company plans to submit a new drug application to the U.S. Food and Drug Administration by mid-2024.

According to a research note by Citi analysts, the drug has demonstrated faster efficacy compared to its competitors Restasis and Xiidra, positioning it for a substantial market share in the United States. Analysts project an estimated earnings-per-share increase of approximately 3% for every $100 million in sales by 2026. The U.S. dry-eye treatment market, where Alcon is listed, is valued between $1.5 billion and $2 billion, as stated by Citi.

Additionally, Alcon successfully met secondary goals, including the promotion of rapid and sustained tear production.

Related posts
News

Which Crypto Is Best To Buy And Tipped As The Safest Investment In 2025: Shiba Inu Or Remittix?

2 Mins read
The crypto market appears to be confident for the latter stages of 2025, having already faced volatility over the past year. Investors…
News

7 Token Presales to Watch in 2025: Blazpay ($BLAZ) Takes the Lead

4 Mins read
The world of token presales has always attracted attention, but 2025 is shaping up to be a pivotal year. With a crowded…
News

Naira rallies to N1,455/$; reserves hit $43bn

5 Mins read
The positive rally of the local currency against the dollar continued yesterday with the naira exchanging at N1,455 to one dollar even…

Leave a Reply

Your email address will not be published. Required fields are marked *

20 − = 11